TransMedics Group (NASDAQ:TMDX) Announces Earnings Results

TransMedics Group (NASDAQ:TMDX) posted its quarterly earnings data on Monday. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.16), Briefing.com reports. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The company had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. During the same quarter in the previous year, the firm posted ($0.12) earnings per share. The company’s quarterly revenue was up 63.7% on a year-over-year basis. TransMedics Group updated its FY 2024 guidance to EPS.

TransMedics Group Price Performance

Shares of TMDX traded down $38.27 during trading hours on Tuesday, hitting $87.97. 2,867,263 shares of the stock were exchanged, compared to its average volume of 871,945. The stock’s 50-day moving average price is $147.58 and its two-hundred day moving average price is $140.19. TransMedics Group has a 12-month low of $36.42 and a 12-month high of $177.37. The company has a debt-to-equity ratio of 2.67, a quick ratio of 8.48 and a current ratio of 9.37. The company has a market cap of $2.93 billion, a price-to-earnings ratio of 2,184.50 and a beta of 1.99.

Insider Buying and Selling at TransMedics Group

In related news, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at approximately $9,457,269.06. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other TransMedics Group news, insider Tamer I. Khayal sold 2,958 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $156.77, for a total value of $463,725.66. Following the transaction, the insider now directly owns 20,843 shares in the company, valued at $3,267,557.11. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction on Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the completion of the sale, the chief executive officer now owns 61,643 shares in the company, valued at $9,457,269.06. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 64,205 shares of company stock worth $9,981,907. Corporate insiders own 7.00% of the company’s stock.

Wall Street Analysts Forecast Growth

TMDX has been the subject of a number of research reports. Needham & Company LLC lowered their price target on TransMedics Group from $208.00 to $109.00 and set a “buy” rating for the company in a research report on Tuesday. Piper Sandler reiterated an “overweight” rating and issued a $180.00 target price on shares of TransMedics Group in a research report on Monday, October 7th. Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. Stephens upped their target price on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Finally, Canaccord Genuity Group reduced their price target on TransMedics Group from $169.00 to $109.00 and set a “buy” rating for the company in a report on Tuesday. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $145.90.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.